Kaken Pharmaceutical revised downward its consolidated sales forecast for the fiscal year ending March 2026 to 76.9 billion yen, down 10.9% year-over-year, due to postponing the recognition of milestone income of approximately 11.1 billion yen from the license agreement with Johnson & Johnson to the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4521","jir_company_name":"Kaken Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4521-20260422-01.pdf","jir_short_summary":"Kaken Pharmaceutical revised downward its consolidated sales forecast for the fiscal year ending March 2026 to 76.9 billion yen, down 10.9% year-over-year, due to postponing the recognition of milestone income of approximately 11.1 billion yen from the license agreement with Johnson & Johnson to the fiscal year ending March 2027.","jir_summary":"### Overview of Earnings Forecast Revision\nKaken Pharmaceutical Co., Ltd. achieved a milestone on April 1, 2026, under its license agreement with Johnson & Johnson. However, the initially planned milestone income of 70 million USD (approximately 11.1 billion yen) will be recognized not in the fiscal year ending March 2026 but postponed to the fiscal year ending March 2027. Accordingly, the consolidated earnings forecast for the fiscal year ending March 2026 has been downward revised to net sales of 76,900 million yen (down 10.9% from previous forecast), operating income of \u25b3900 million yen, ordinary income of \u25b3200 million yen, and net income attributable to owners of parent of 2,100 million yen (down 8.7%).\n\n### Background of Revision and Dividend Outlook\nIn addition to the timing change of milestone income recognition, this revision reflects adjustments due to efficiency improvements in R&D investments aimed at medium- to long-term growth and the impact of sales of policy holding shares based on the reduction policy announced in May 2024. Meanwhile, there is currently no change to the dividend forecast for the fiscal year ending March 2026.","jir_financial_highlights":"Net Sales: 76,900 million yen (Down 10.9% from previous forecast)\nOperating Income: \u25b3900 million yen (Decreased from previous forecast (2,100 million yen \u2192 \u25b3900 million yen))\nOrdinary Income: \u25b3200 million yen (Decreased from previous forecast (2,800 million yen \u2192 \u25b3200 million yen))\nNet Income Attributable to Owners of Parent: 2,100 million yen (Down 8.7% from previous forecast)\nNet Income per Share: 55 yen 39 sen (Decreased from previous forecast)","jir_category":"","jir_hashtags":"#KakenPharmaceutical, #EarningsForecastRevision, #JapaneseStocks","jir_key_figures":"Milestone income: approximately 11.1 billion yen (70 million USD, based on 1 USD = 158 yen), timing postponed to fiscal year ending March 2027\nNet sales forecast for fiscal year ending March 2026: 76,900 million yen (down 10.9% from previous forecast)\nNet income attributable to owners of parent forecast for fiscal year ending March 2026: 2,100 million yen (down 8.7% from previous forecast)","jir_meta_title":"\u3010Kaken Pharmaceutical\u3011Revision of Earnings Forecast for Fiscal Year Ending March 2026\uff5cNet Sales 7.69 Billion Yen (Down 10.9% YoY)","jir_meta_description":"Kaken Pharmaceutical has postponed the recognition of milestone income under the license agreement with Johnson & Johnson to the fiscal year ending March 2027, revising down its net sales forecast for the fiscal year ending March 2026 to 76,900 million yen. Dividend forecast remains unchanged.","jir_og_title":"\u3010Kaken Pharmaceutical\u3011Revision of Earnings Forecast for Fiscal Year Ending March 2026\uff5cNet Sales 7.69 Billion Yen (Down 10.9% YoY)","jir_og_description":"Due to the timing change in milestone income recognition, Kaken Pharmaceutical has revised its earnings forecast for the fiscal year ending March 2026. Net sales have been revised downward to 76,900 million yen. Dividends will remain unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9082,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-41719","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n